1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Pharma Foods International Co., Ltd.

Pharma Foods International Co., Ltd.

TTSE:2929
677.00
JPY
-1.00
(-0.15%)
28.65BMarket Cap
Dec 16Next Earn
Pharma Foods International Co., Ltd.
TSE:2929
(Tokyo Stock Exchange)

Recent

price

677.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
JPY
40.81
42.84
52.13
64.87
62.3
74.76
119.2
162.66
273.58
362.75
528.69
1,609.18
2,074.36
2,374.66
2,185.12
- -
- -
Revenue per Share
0.65
-1.98
2.55
11.46
0.34
-6.49
0.89
3.49
10.8
17.21
23.76
132.2
-12.89
106.7
112.69
- -
- -
Basic EPS, GAAP
-1.4
-0.96
7.53
0.35
-8.91
-9.72
-3.67
6.47
12.57
-6.54
-50.24
198.43
-225.31
198.08
158.68
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.48
9.98
30.02
20.02
22.01
- -
- -
Dividend per Share
98.38
97.62
101.07
113.34
127.54
118.92
120.34
123.5
134.08
148.63
168.89
291.2
243.61
333.85
412.69
- -
414.54
Book Value per Share
98.33
97.57
101.02
113.29
127.37
118.76
119.14
113.67
124.81
140.41
162.07
284.84
233.1
325.6
406.38
- -
409.75
Tangible Book Value per Share
24
24
24
24
26
29
29
29
29
29
29
29
29
29
28
29
28
Basic Weighted Avg Shares
959
1,007
1,225
1,525
1,615
2,166
3,461
4,723
7,943
10,533
15,353
46,752
60,185
68,572
62,147
- -
- -
Sales/Revenue/Turnover
1.21
3.94
12.9
21.44
6.21
-8.46
17.29
2.31
4.21
5.83
5.07
12.23
1.88
5.37
8.39
- -
- -
Operating Margin (%)
41
33
25
25
25
30
43
57
51
54
114
138
469
474
808
732
- -
Depreciation Expense
15
-47
60
269
9
-188
26
101
314
500
690
3,841
-374
3,081
3,205
- -
- -
Net Income, GAAP
20.48
- -
8.55
8.23
24.44
- -
8.4
15
- -
24.05
18.51
33.37
126.28
13.04
36.31
- -
- -
Effective Tax Rate (%)
1.59
-4.63
4.9
17.67
0.55
-8.68
0.75
2.15
3.95
4.75
4.49
8.22
-0.62
4.49
5.16
- -
- -
Profit Margin (%)
1,143
1,146
1,188
1,578
2,327
2,189
2,645
3,282
3,231
4,550
4,600
6,955
718
3,156
4,112
- -
3,821
Working Capital
- -
3
2
2
1
- -
429
1,088
920
2,045
2,302
1,458
697
1,741
1,231
- -
951
LT Debt
2,312
2,294
2,375
2,666
3,691
3,453
3,497
3,592
3,910
4,316
4,905
8,463
7,072
9,630
11,585
- -
12,046
Total Equity
-2.16
- -
2.65
7.26
-0.64
- -
-1.11
1.62
- -
6.78
7.47
31.5
-1.43
11.55
10.88
- -
- -
Return on Invested Capital (%)
0.67
- -
2.49
9.92
0.29
- -
0.77
2.18
- -
7.81
8.76
35.24
-2.04
11.64
11.15
- -
- -
Return on Capital (%)
0.66
-2.02
2.57
10.69
0.28
-5.26
0.75
2.86
8.39
12.18
14.97
57.47
-4.82
36.9
30.21
- -
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Jul'24
Oct'25
Jan'25
ST Debt
15,660
- -
11,493
LT Borrowings
1,231
- -
951
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
28
28
29
Market Capitalization
30,908
27,062
28,652

Working Capital

JPY

•

in mil. unless spec.
Jul'24
Oct'25
Jan'25
Total Current Assets
27,275
- -
23,313
Cash, Cash Equivalents & STI
15,666
- -
11,106
Accounts Receivable, Net
4,038
- -
3,817
Inventories
6,717
- -
6,886
Total Current Liabilities
23,163
- -
19,492
Payables & Accruals
- -
- -
- -
ST Debt
15,660
- -
11,493
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16,142
15,510
15,519
14,976
62,147
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9.92
16.75
38.76
48.05
112.69
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
22.01
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Pharma Foods International Co., Ltd. develops and sells functional food ingredients, pharmaceuticals, and biomedical products in Japan and internationally. Founded in 1997 and headquartered in Kyoto, the company operates through three main segments: BtoB, providing functional ingredients such as PharmaGABA® for stress relief and sleep improvement, Bonepep® for bone growth, Cerepron® for skin whitening, Runpep® for blood flow enhancement, HGP® for hair growth, and Pharma Biomix®; BtoC, offering e-commerce and wholesale of supplements like Tamagosamin® with iHA® for joint health, Newmo® Hair Growth Formula, and cosmetics including Eyelash Deluxe WMOA; and Bio Medical, focusing on drug discovery via proprietary ALAgene® antibody production technology from chickens and proteome analysis services. Through subsidiaries like Meiji Yakuhin Co., Ltd., it manufactures and sells contract pharmaceuticals (CMO), consumer health care (CHC) products such as Shiboranaito® GOLD, and new own-brand beverages under Meiseki Lab. The company targets food manufacturers, pharmaceutical firms, drugstores, and consumers focused on immunity, aging, and nervous system health, with geographic operations spanning Japan, North America, South Korea, Southeast Asia, and planned expansion into Vietnam via a joint venture health food factory. Recent developments include a November 2025 partnership with The University of Tokyo for AI-driven next-generation antibody drug discovery; a September 2025 strategic license agreement for an ALAgene®-derived antibody therapeutic achieving Phase I clinical milestones; November 2023 acquisition of international ISO/IEC 17025 certification for GABA testing; September 2023 takeover of Daicel Corporation's healthcare e-commerce business; July 2023 business alliance with Takara Bio Inc.; February 2024 agreement with NEDO on a five-year Bio Manufacturing Revolution project for eggshell membrane applications in fibers, battery materials, and biostimulants; and January 2024 launch of K-3, a GABA-containing lactobacillus ferment as Japan's first biostimulant agricultural material.